Skip to content
PreclinicalResearch compoundLimited evidence

Baicalein

Skullcap flavone (5,6,7-trihydroxyflavone), a GABA-A modulator with antioxidant and calming profile, preclinical data only.

NootropicAnxiolyticAnxiolyticMoodGABAnoo.affects.moodnoo.affects.neuroprotectionnoo.affects.anti-inflammatory

Pharmacology

ClassAnxiolytic · Mood
Primary targetGABA-A receptor positive allosteric modulation
Targets4 receptor targets
Half-lifeNot well characterized in humans, likely a few hours; rapid glucuronidation lowers the free fraction
OnsetNo standardized human data (hours-scale in animal models)
EvidenceLimited evidence
Affected systemsGABAnoo.affects.moodnoo.affects.neuroprotectionnoo.affects.anti-inflammatory

Contents

WHAT IS BAICALEIN?

Detailed overview

Baicalein (5,6,7-trihydroxyflavone) is a flavone from the root of Baikal skullcap (Scutellaria baicalensis) and related skullcap species, long used in traditional Chinese medicine. Its three adjacent hydroxyl groups give it strong metal-chelating and free-radical-scavenging antioxidant activity, and the compound also acts as a positive allosteric modulator of the GABA-A receptor, producing mild anxiolytic and calming effects in animal models. It inhibits lipoxygenase and other inflammatory enzymes and shows neuroprotective activity in numerous rodent and fish models. There is no human clinical evidence for a nootropic/anxiolytic use: the effects are mainly preclinical, and poor oral bioavailability leaves the human assessment largely unexplored.

Mechanism

GABA-A PAM + antioxidant / LOX-inhibiting flavone

Evidence

Preclinical only (no human RCT)

Legal status

Herbal extract / dietary-supplement ingredient

Receptor profile

  • Antioxidant / oxidative-stress reductionStrong
  • GABA-A receptors (benzodiazepine site)Moderate
  • Lipoxygenase (12/15-LOX) inhibitionModerate
  • Serotonin / dopamine signalingWeak

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • No established human dosing or safety profile: evidence comes largely from animal and cell studies
  • May inhibit drug-metabolizing enzymes (CYP3A4, CYP1A2, UGT), altering blood levels of other agents
  • May affect blood-clotting and platelet-aggregation pathways (theoretical bleeding risk)
  • Poor oral bioavailability due to rapid glucuronidation, so effects vary between individuals
  • Theoretical sedation or drowsiness at higher doses from GABAergic modulation
  • Possible gastrointestinal upset with skullcap (Scutellaria) extracts

Contraindications · 4

  • Pregnancy and breastfeeding: safety not established, avoid
  • Anticoagulant or antiplatelet therapy, or before planned surgery: possible bleeding risk
  • Concurrent use of CYP3A4/CYP1A2-metabolized drugs: interaction risk
  • Not an approved medicine; herbal/research compound without standardized dosing, medical consultation advised

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Skullcap flavone (5,6,7-trihydroxyflavone), a GABA-A modulator with antioxidant and calming profile, preclinical data only.

Telegram

Have a question about Baicalein?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC15H10O5
UpdatedJuly 10, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: July 10, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.